Allergan Plc is no longer looking at selling its women’s health business, Chief Executive Officer Brent Saunders said on Tuesday.
“For Women’s Health, we have concluded that the highest value proposition for this business at this time is to continue managing it and optimizing it,” Saunders said.
Saunders also said the company’s anti-infectives business will “more likely than not” be sold over the near term.
The company had said in May it was looking to sell both its women’s health and infectious disease units following a review of its businesses.
By Tamara Mathias
Source: Reuters
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
